The future of the pharmaceutical field of long-term main line logical space is large, several major sub-fields are optimistic

Pharmaceutical Network Market Analysis: Since the first quarter, some medical devices, testing equipment, raw materials, blood products and other demand is obvious, the market has been growingThe industry believes that, as far as the current situation is concerned, the future of the pharmaceutical field of the main line logic space is larger, it is recommended to pay attention to vaccines, blood products, growth hormone, in vitro diagnosis and other major sub-fields
At present, the vaccine industry is in the long-term, with a number of domestic heavy vaccine varieties (including multi-price seedlings and new vaccines, etc.) have been approved, as well as follow-up support to encourage the promotion of policies, the public awareness of disease prevention, vaccine research and development and production investment is increasing, the industry will usher in a period of rapid developmentData show that from 2013 to 2018, China's vaccination market has maintained a steady growth trend, the market size in 2018 has reached 27.6 billion yuan, the forecast is 2030 is expected to reach 100.9 billion yuan
The industry believes that in the short term, it is expected that in 2020 domestic 13-price pneumonia vaccine, HPV vaccine is expected to be approved on the market, the new vaccine area of heavy products will continue to maintain rapid growthIn the long run, the replacement and upgrading of multi-price vaccines will be the way forward
At present, China's blood products sub-sector industry is in the mature stage, high barriers, there are no new entrants, blood products enterprise profitability is good, the future is expected to maintain stable growth, the key to see the number of pulp stations and product structureData show that in 2019, the amount of pulp collection is about 9100 tons, the year-on-year growth rate of only 5.8%, can be seen in China's blood products industry raw material plasma supply growth slowed down, at the same time, the issuance of gradually concentrated to leading enterprises
In the medium to long term, the increase in demand for blood products is more likely to come from possible clinical cognitive improvements, waiting to be observedThe annual compound growth rate of the blood products industry is stable at about 10-15%, and in general, blood products companies with long-term pulping capacity and strong operation and management capabilities have strong competitivenessIn addition, immunoglobulin and coagulation factor products will become the driving force of the industry's future growth, some varieties of domestic replacement space is broad
Domestic injection recombinant human growth hormone market to maintain high-speed growth market trend, growth hormone industry in recent years accelerated development, 2018 has been the volume of high-speed growth period, high industry climateWith the improvement of the competitiveness of domestic enterprises and the price advantage of domestic products, the market space of imported products is gradually reduced, the subsequent product upgrade volume is expected to bring about a rapid increase in the market share
The field of in vitro diagnosis is divided into biochemical diagnosis, immunodiagnosis, molecular diagnosis, microbial diagnosis, clotting diagnosis, tissue diagnosis, etcThe industry believes that the current IVD market presents the rapid release of the mid-market, high-end market gradually open up the pattern, the future technology update and domestic replacement still has a larger space, the domestic industry concentration is low, excellent leading listed enterprises will benefit from market expansion and concentration, it is recommended to pay attention to in vitro diagnostic leader Antu Bio, Wanfu Bio and so on
Among them, Antu Bio is the leading domestic immunodiagnostic and microbial diagnostic enterprises, covering the field of immunity, biochemistry, microorganisms and other testing, Wanfu Bio as a leading domestic POCT leading enterprise, in the field of in vitro diagnostic continuous investment in research and development costs for product research and development, research and development costs in the last three years accounted for more than 9% of operating income
Data show that China's medical device industry in recent years, the compound growth rate has continued to maintain around 15% In 2018, china's medical device manufacturers main income of about 638 billion yuan, it is expected that by 2021-2022, medical device manufacturers' main income is expected to exceed trillion yuan.